ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.909,14
-0,25%
S&P 500
5.881,63
-0,43%
Dow Jones
42.544,22
-0,07%
Euro vs US Dollar
1,03498
0,00%
Bitcoin
93.472,48
0,10%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Evaxion Biotech AS (EVAX)

  7. Evaxion Biotech AS (EVAX) News

EVAX

Evaxion Biotech AS (EVAX)

Evaxion Biotech AS
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:EVAX
DatumZeitQuelleÜberschriftSymbolFirma
30/12/202414h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
30/12/202414h00GlobeNewswire Inc.Evaxion announces plan to implement ADS ratio changeNASDAQ:EVAXEvaxion Biotech AS
26/12/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
17/12/202423h09Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:EVAXEvaxion Biotech AS
17/12/202414h16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
17/12/202414h00GlobeNewswire Inc.Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equityNASDAQ:EVAXEvaxion Biotech AS
12/12/202414h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
12/12/202414h00GlobeNewswire Inc.Evaxion establishes new AI-derived precision cancer vaccine conceptNASDAQ:EVAXEvaxion Biotech AS
09/12/202415h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
09/12/202414h00GlobeNewswire Inc.Evaxion announces 2025 milestones reflecting continued strong strategy executionNASDAQ:EVAXEvaxion Biotech AS
05/12/202422h53Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:EVAXEvaxion Biotech AS
03/12/202412h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
02/12/202414h00GlobeNewswire Inc.Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology CongressNASDAQ:EVAXEvaxion Biotech AS
18/11/202422h30Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:EVAXEvaxion Biotech AS
13/11/202415h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
13/11/202414h00GlobeNewswire Inc.Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listingNASDAQ:EVAXEvaxion Biotech AS
13/11/202413h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
13/11/202413h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
12/11/202414h00GlobeNewswire Inc.Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1NASDAQ:EVAXEvaxion Biotech AS
31/10/202415h20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
31/10/202413h00GlobeNewswire Inc.Evaxion announces business update and third quarter 2024 financial resultsNASDAQ:EVAXEvaxion Biotech AS
28/10/202414h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
28/10/202413h00GlobeNewswire Inc.Evaxion to announce business update and third quarter 2024 financial results on October 31NASDAQ:EVAXEvaxion Biotech AS
09/10/202417h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
09/10/202414h00GlobeNewswire Inc.Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trialsNASDAQ:EVAXEvaxion Biotech AS
04/10/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
03/10/202414h00GlobeNewswire Inc.Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platformNASDAQ:EVAXEvaxion Biotech AS
03/10/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
01/10/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
26/09/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
 Showing the most relevant articles for your search:NASDAQ:EVAX

Kürzlich von Ihnen besucht

AQSE
WHEA.GB
State Street Global Advi...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten